Buspirone (Buspar) Dosing
For adults with generalized anxiety disorder, start buspirone at 7.5 mg twice daily (15 mg/day total), increase by 5 mg/day every 2-3 days as tolerated to a target of 15-30 mg/day divided twice or three times daily, with a maximum of 60 mg/day. 1
Standard Adult Dosing
- Starting dose: 7.5 mg twice daily (15 mg/day total)
- Titration: Increase by 5 mg/day every 2-3 days as tolerated
- Target therapeutic range: 15-30 mg/day divided BID or TID
- Maximum dose: 60 mg/day
- Dosing frequency: Either twice daily (BID) or three times daily (TID) are equally effective 2
The FDA label indicates buspirone is rapidly absorbed with peak levels occurring 40-90 minutes after dosing, and has a short elimination half-life of 2-3 hours 1. Research confirms no significant difference in efficacy or safety between BID versus TID dosing regimens at 30 mg/day 2.
Food Timing Considerations
Take buspirone consistently either always with food or always without food. Food significantly increases buspirone absorption—the AUC and peak concentration increase by 84% and 116% respectively when taken with food 1. This suggests food decreases first-pass metabolism. Consistency in administration timing relative to meals is critical to maintain stable drug levels 1.
Hepatic Impairment
Buspirone is contraindicated in severe hepatic impairment. In patients with hepatic dysfunction, steady-state AUC increases 13-fold compared to healthy subjects, with elimination half-life doubling 1. The drug undergoes extensive first-pass metabolism via CYP3A4, and hepatic disease dramatically impairs clearance 3. If mild-to-moderate hepatic impairment exists and buspirone must be used, start at the lowest possible dose with very cautious titration.
Renal Impairment
Use caution in renal impairment; consider dose reduction. Steady-state AUC increases 4-fold in patients with creatinine clearance 10-70 mL/min/1.73 m² compared to healthy subjects 1. While not absolutely contraindicated like severe hepatic disease, the substantial increase in drug exposure warrants starting at lower doses (e.g., 5 mg BID) and slower titration 3.
Elderly Patients
No dose adjustment is required based on age alone. Pharmacokinetic studies show no significant differences in buspirone AUC or Cmax between elderly and younger patients 1. Clinical trials in over 600 patients aged ≥65 years demonstrated similar safety and efficacy profiles to younger adults 4. The typical starting dose of 15 mg/day (mean effective dose 18 mg/day) was well-tolerated in elderly patients, including those on multiple concomitant medications for chronic conditions 5, 4.
Important Clinical Considerations
- Onset of action: Unlike benzodiazepines, buspirone requires 2-4 weeks for full anxiolytic effect
- Bioavailability: Only ~4% absolute bioavailability due to extensive first-pass metabolism 6
- No accumulation: After 9 days of dosing, no accumulation of parent drug or active metabolite (1-PP) occurs 6
- Linear pharmacokinetics: Dose-proportional over 10-40 mg range, though repeated dosing may lead to somewhat higher levels than predicted from single doses 1
Drug Interactions
Avoid strong CYP3A4 inhibitors or reduce buspirone dose substantially. Coadministration with verapamil, diltiazem, erythromycin, or itraconazole substantially increases buspirone plasma concentrations 6. Conversely, rifampin decreases buspirone levels nearly 10-fold 6. Monitor for prolonged prothrombin time if combined with warfarin 1.
Common Pitfalls
- Starting at too high a dose in hepatically impaired patients—this population requires extreme caution
- Inconsistent administration relative to meals, causing variable drug levels
- Expecting immediate anxiolytic effects like benzodiazepines—counsel patients about delayed onset
- Not accounting for CYP3A4 interactions, particularly with commonly used medications like calcium channel blockers or macrolide antibiotics